- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05494944
Low Power ThULEP for Prostate Size More Than 80 gm
August 9, 2022 updated by: Samer Morsy, Kasr El Aini Hospital
Low Power Thulium Enucleation of Prostate More Than 80 Grams
Feasibility and Efficacy of lower power thulium enucleation of prostate more than 80 grams
Study Overview
Detailed Description
Intra operative outcome and postoperative follow up of IPSS score and IEFF score at 6 months.
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cairo, Egypt, 12334
- Samer Morsy
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- BPH patients with failed medical treatment
- Refractory retention
- Hematuria
- Bladder stones
- Renal impairment due to BPH
Exclusion Criteria:
- Neurogenic patients
- stricture urethra
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: ThuLEP group
|
Minimal invasive prostate intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Timing of complete adenoma removal ( enucleation time in minutes)
Time Frame: During operation
|
During operation
|
|
International prostate symptoms score IPSS less than 7 which is good outcome
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
International Index of Erectile Function- 5 score more than 12 which is a good outcome
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2019
Primary Completion (Actual)
March 30, 2022
Study Completion (Actual)
March 30, 2022
Study Registration Dates
First Submitted
August 5, 2022
First Submitted That Met QC Criteria
August 9, 2022
First Posted (Actual)
August 10, 2022
Study Record Updates
Last Update Posted (Actual)
August 12, 2022
Last Update Submitted That Met QC Criteria
August 9, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Urology department
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.